
Kathrin H Kirsch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7914500/publications.pdf Version: 2024-02-01



Катноім Н Кіресн

#	Article	IF	CITATIONS
1	Multiplexed CRISPR/CAS9â€mediated engineering of preâ€clinical mouse models bearing native human B cell receptors. EMBO Journal, 2021, 40, e105926.	7.8	24
2	Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies. Immunity, 2021, 54, 2859-2876.e7.	14.3	19
3	A polymorphism in the lysyl oxidase propeptide domain accelerates carcinogen-induced cancer. Carcinogenesis, 2018, 39, 921-930.	2.8	7
4	Oneâ€step <scp>CRISPR</scp> /Cas9 method for the rapid generation of human antibody heavy chain knockâ€in mice. EMBO Journal, 2018, 37, .	7.8	28
5	UXT Is a LOX-PP Interacting Protein That Modulates Estrogen Receptor Alpha Activity in Breast Cancer Cells. Journal of Cellular Biochemistry, 2017, 118, 2347-2356.	2.6	19
6	A truncated phosphorylated p130Cas substrate domain is sufficient to drive breast cancer growth and metastasis formation in vivo. Tumor Biology, 2016, 37, 10665-10673.	1.8	3
7	Identification of Novel Crk-associated Substrate (p130Cas) Variants with Functionally Distinct Focal Adhesion Kinase Binding Activities. Journal of Biological Chemistry, 2015, 290, 12247-12255.	3.4	6
8	Differential Recognition Preferences of the Three Src Homology 3 (SH3) Domains from the Adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3). Journal of Biological Chemistry, 2015, 290, 25275-25292.	3.4	33
9	p130Cas acts as survival factor during PMA-induced apoptosis in HL-60 promyelocytic leukemia cells. International Journal of Biochemistry and Cell Biology, 2013, 45, 531-535.	2.8	10
10	Expression of a phosphorylated substrate domain of p130Cas promotes PyMT-induced c-Src-dependent murine breast cancer progression. Carcinogenesis, 2013, 34, 2880-2890.	2.8	5
11	Insulin Inhibits Lipolysis in Adipocytes via the Evolutionarily Conserved mTORC1-Egr1-ATGL-Mediated Pathway. Molecular and Cellular Biology, 2013, 33, 3659-3666.	2.3	130
12	Inhibition of CIN85-Mediated Invasion by a Novel SH3 Domain Binding Motif in the Lysyl Oxidase Propeptide. PLoS ONE, 2013, 8, e77288.	2.5	15
13	Regulation of p130Cas/BCAR1 Expression in Tamoxifen-Sensitive and Tamoxifen-Resistant Breast Cancer Cells by EGR1 and NAB2. Neoplasia, 2012, 14, 108-120.	5.3	23
14	Recombinant Lysyl Oxidase Propeptide Protein Inhibits Growth and Promotes Apoptosis of Pre-Existing Murine Breast Cancer Xenografts. PLoS ONE, 2012, 7, e31188.	2.5	38
15	Blimp1 Activation by AP-1 in Human Lung Cancer Cells Promotes a Migratory Phenotype and Is Inhibited by the Lysyl Oxidase Propeptide. PLoS ONE, 2012, 7, e33287.	2.5	27
16	The Ras Signaling Inhibitor LOX-PP Interacts with Hsp70 and c-Raf To Reduce Erk Activation and Transformed Phenotype of Breast Cancer Cells. Molecular and Cellular Biology, 2011, 31, 2683-2695.	2.3	35
17	The Lysyl Oxidase Propeptide Interacts with the Receptor-Type Protein Tyrosine Phosphatase Kappa and Inhibits 1²-Catenin Transcriptional Activity in Lung Cancer Cells. Molecular and Cellular Biology, 2011, 31, 3286-3297.	2.3	40
18	EGR1, EGR2, and EGR3 activate the expression of their coregulator NAB2 establishing a negative feedback loop in cells of neuroectodermal and epithelial origin. Journal of Cellular Biochemistry, 2010, 111, 207-217.	2.6	61

KATHRIN H KIRSCH

#	Article	IF	CITATIONS
19	Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicinâ€induced apoptosis. Journal of Cellular Biochemistry, 2010, 111, 1160-1168.	2.6	23
20	Characterization of Recombinant Lysyl Oxidase Propeptide. Biochemistry, 2010, 49, 2962-2972.	2.5	34
21	A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer. Cancer Research, 2009, 69, 6685-6693.	0.9	64
22	Expression of a phosphorylated p130 ^{Cas} substrate domain attenuates the phosphatidylinositol 3â€kinase/Akt survival pathway in tamoxifen resistant breast cancer cells. Journal of Cellular Biochemistry, 2009, 107, 364-375.	2.6	20
23	The Lysyl Oxidase Pro-peptide Attenuates Fibronectin-mediated Activation of Focal Adhesion Kinase and p130Cas in Breast Cancer Cells. Journal of Biological Chemistry, 2009, 284, 1385-1393.	3.4	58
24	Structure and function analysis of the CMS/CIN85 protein family identifies actin-bundling properties and heterotypic-complex formation. Journal of Cell Science, 2007, 120, 2366-2377.	2.0	47
25	The Tumor Suppressor Activity of the Lysyl Oxidase Propeptide Reverses the Invasive Phenotype of Her-2/neu–Driven Breast Cancer. Cancer Research, 2007, 67, 1105-1112.	0.9	99
26	Repression of BCL2 by the Tumor Suppressor Activity of the Lysyl Oxidase Propeptide Inhibits Transformed Phenotype of Lung and Pancreatic Cancer Cells. Cancer Research, 2007, 67, 6278-6285.	0.9	83
27	Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nature Cell Biology, 2007, 9, 470-478.	10.3	189
28	A B Cell Receptor with Two Igα Cytoplasmic Domains Supports Development of Mature But Anergic B Cells. Journal of Experimental Medicine, 2004, 199, 855-865.	8.5	27
29	A p130Cas tyrosine phosphorylated substrate domain decoy disrupts v-crk signaling. BMC Cell Biology, 2002, 3, 18.	3.0	21
30	Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II. Oncogene, 2001, 20, 951-961.	5.9	33
31	The Adapter Type Protein CMS/CD2AP Binds to the Proto-oncogenic Protein c-Cbl through a Tyrosine Phosphorylation-regulated Src Homology 3 Domain Interaction. Journal of Biological Chemistry, 2001, 276, 4957-4963.	3.4	75
32	Direct Binding of p130Cas to the Guanine Nucleotide Exchange Factor C3G. Journal of Biological Chemistry, 1998, 273, 25673-25679.	3.4	83